1. Home
  2. UEIC vs IBIO Comparison

UEIC vs IBIO Comparison

Compare UEIC & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.08

Market Cap

48.3M

ML Signal

HOLD

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$2.39

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
IBIO
Founded
1986
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.3M
50.4M
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
UEIC
IBIO
Price
$4.08
$2.39
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$9.25
$4.00
AVG Volume (30 Days)
85.3K
3.1M
Earning Date
02-19-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$390,997,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.11
P/E Ratio
N/A
N/A
Revenue Growth
2.35
185.71
52 Week Low
$2.69
$0.56
52 Week High
$11.02
$6.89

Technical Indicators

Market Signals
Indicator
UEIC
IBIO
Relative Strength Index (RSI) 70.77 58.43
Support Level $3.81 $2.10
Resistance Level $4.07 $2.89
Average True Range (ATR) 0.16 0.30
MACD 0.05 -0.02
Stochastic Oscillator 91.30 52.34

Price Performance

Historical Comparison
UEIC
IBIO

About UEIC Universal Electronics Inc.

Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: